Physician profile
Deepti Gupta
NPI 1326281353
$7,613.07
in general payments reported to CMS, 2019-2025
8 companies · $4,256 in 2025
The $4,256 reported for 2025 was more than what 82% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.96 · 2020: $1,480 · 2023: $1,225 · 2024: $590 · 2025: $4,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,200 · Consulting Fee: $1,500 · Food and Beverage: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,200.00 |
| Consulting Fee | $1,500.00 |
| Food and Beverage | $371.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $2,350.10 | 2025 | Zelsuvmi |
| Pfizer INC. | $1,633.61 | 2019-2025 | |
| Nobelpharma America, LLC | $1,625.00 | 2023-2024 | |
| Incyte Corporation | $1,500.00 | 2025 | |
| Chiesi USA, INC. | $300.00 | 2025 | Filsuvez |
| Pierre Fabre Pharmaceuticals, INC. | $128.61 | 2024 | Hemangeol |
| Verrica Pharmaceuticals INC. | $61.09 | 2024 | |
| Arcutis Biotherapeutics, INC. | $14.66 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepti Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.